-
ITF Therapeutics LLC Announces U.S. Commercial Availability of DUVYZAT™ (givinostat) for Treatment of Patients With Duchenne Muscular Dystrophy
First nonsteroidal treatment approved for patients six years of age and older with DMD regardless […]
-
ITF Therapeutics Announces U.S. Commercial Availability of DUVYZAT™ (givinostat) for Treatment of Duchenne
PPMD is pleased to learn that DUVYZAT (givinostat) is now commercially available in the United […]
-
FDA OKs clinical trial of DMD stem cell therapy MyoPAXon
The U.S. Food and Drug Administration (FDA) has given the green light for Myogenica to […]
-
I wish more facilities considered accessibility and privacy
A few years ago, my wife, Wendy, and I took a mini-vacation to Philadelphia with […]
-
Navigating the Approved Therapy Landscape
The approved therapy landscape has changed drastically in Duchenne, especially over the last year. With […]
-
PPMD’s 30th Annual Conference Session Recordings
Thank you to everyone who helped us celebrate three decades of progress, community, and resilience […]
-
Expanding Duchenne Clinical Trial Criteria: A Crucial Step Forward
READ THE FULL PRESS RELEASE HERE Introduction The journey towards finding effective treatments for Duchenne […]
-
Breakthrough in skeletal muscle regeneration
In a finding that opens the door to the development of targeted therapies for various […]
-
How a son’s MRI stirred up fields of dreams and hopes
This week, one of my boys had to get an MRI. Three of my four […]
-
CureDuchenne Celebrates FDA’s Launch of Rare Disease Innovation Hub
We at CureDuchenne are excited to acknowledge the recent announcement by the United States Food […]
